RETRACTED: New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics
Prostate adenocarcinoma accounts for more than 20% of deaths among males due to cancer. It is the fifth-leading cancer diagnosed in males across the globe. The mortality rate is quite high due to prostate cancer. Despite the fact that advancements in diagnostics and therapeutics have been made, ther...
| मुख्य लेखकों: | , , , , |
|---|---|
| स्वरूप: | लेख |
| भाषा: | English |
| प्रकाशित: |
Frontiers Media S.A.
2023-08-01
|
| श्रृंखला: | Frontiers in Oncology |
| विषय: | |
| ऑनलाइन पहुंच: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1193736/full |
| _version_ | 1827317467183054848 |
|---|---|
| author | Neha Thakur Sameer Quazi Sameer Quazi Sameer Quazi Sameer Quazi Sameer Quazi Bindu Naik Saurabh Kumar Jha Saurabh Kumar Jha Saurabh Kumar Jha Pallavi Singh |
| author_facet | Neha Thakur Sameer Quazi Sameer Quazi Sameer Quazi Sameer Quazi Sameer Quazi Bindu Naik Saurabh Kumar Jha Saurabh Kumar Jha Saurabh Kumar Jha Pallavi Singh |
| author_sort | Neha Thakur |
| collection | DOAJ |
| description | Prostate adenocarcinoma accounts for more than 20% of deaths among males due to cancer. It is the fifth-leading cancer diagnosed in males across the globe. The mortality rate is quite high due to prostate cancer. Despite the fact that advancements in diagnostics and therapeutics have been made, there is a lack of effective drugs. Metabolic pathways are altered due to the triggering of androgen receptor (AR) signaling pathways, and elevated levels of dihydrotestosterone are produced due to defects in AR signaling that accelerate the growth of prostate cancer cells. Further, PI3K/AKT/mTOR pathways interact with AR signaling pathway and act as precursors to promote prostate cancer. Prostate cancer therapy has been classified into luminal A, luminal B, and basal subtypes. Therapeutic drugs inhibiting dihydrotestosterone and PI3K have shown to give promising results to combat prostate cancer. Many second-generation Androgen receptor signaling antagonists are given either as single agent or with the combination of other drugs. In order to develop a cure for metastasized prostate cancer cells, Androgen deprivation therapy (ADT) is applied by using surgical or chemical methods. In many cases, Prostatectomy or local radiotherapy are used to control metastasized prostate cancer. However, it has been observed that after 1.5 years to 2 years of Prostatectomy or castration, there is reoccurrence of prostate cancer and high incidence of castration resistant prostate cancer is seen in population undergone ADT. It has been observed that Androgen derivation therapy combined with drugs like abiraterone acetate or docetaxel improve overall survival rate in metastatic hormone sensitive prostate cancer (mHSPC) patients. Scientific investigations have revealed that drugs inhibiting poly ADP Ribose polymerase (PARP) are showing promising results in clinical trials in the prostate cancer population with mCRPC and DNA repair abnormalities. Recently, RISUG adv (reversible inhibition of sperm under guidance) has shown significant results against prostate cancer cell lines and MTT assay has validated substantial effects of this drug against PC3 cell lines. Current review paper highlights the advancements in prostate cancer therapeutics and new drug molecules against prostate cancer. It will provide detailed insights on the signaling pathways which need to be targeted to combat metastasized prostate cancer and castration resistant prostate cancer. |
| first_indexed | 2024-03-09T02:32:50Z |
| format | Article |
| id | doaj.art-bc58d087a0e2481d81d5204e9bafd897 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-24T23:39:18Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-bc58d087a0e2481d81d5204e9bafd8972024-03-15T14:04:10ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-08-011310.3389/fonc.2023.11937361193736RETRACTED: New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeuticsNeha Thakur0Sameer Quazi1Sameer Quazi2Sameer Quazi3Sameer Quazi4Sameer Quazi5Bindu Naik6Saurabh Kumar Jha7Saurabh Kumar Jha8Saurabh Kumar Jha9Pallavi Singh10Department of Biotechnology, Graphic Era (Deemed to be University), Dehradun, Uttarakhand, IndiaDepartment of Chemistry, Akshara First Grade College, Bengaluru, IndiaGenLab Biosolutions Private Limited, Bangalore, Karnataka, IndiaDepartment of Biomedical Sciences, School of Life Sciences, Anglia Ruskin University, Cambridge, United KingdomSchool of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United KingdomSolution Chemistry of Advanced Materials and Technologies (SCAMT) Institute, ITMO University, St. Petersburg, RussiaDepartment of Food Science and Technology, Graphic Era Deemed to be University, Dehradun, Uttarakhand, IndiaDepartment of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida, IndiaDepartment of Biotechnology Engineering and Food Technology, Chandigarh University, Mohali, India0Department of Biotechnology, School of Applied & Life Sciences (SALS), Uttaranchal University, Dehradun, IndiaDepartment of Biotechnology, Graphic Era (Deemed to be University), Dehradun, Uttarakhand, IndiaProstate adenocarcinoma accounts for more than 20% of deaths among males due to cancer. It is the fifth-leading cancer diagnosed in males across the globe. The mortality rate is quite high due to prostate cancer. Despite the fact that advancements in diagnostics and therapeutics have been made, there is a lack of effective drugs. Metabolic pathways are altered due to the triggering of androgen receptor (AR) signaling pathways, and elevated levels of dihydrotestosterone are produced due to defects in AR signaling that accelerate the growth of prostate cancer cells. Further, PI3K/AKT/mTOR pathways interact with AR signaling pathway and act as precursors to promote prostate cancer. Prostate cancer therapy has been classified into luminal A, luminal B, and basal subtypes. Therapeutic drugs inhibiting dihydrotestosterone and PI3K have shown to give promising results to combat prostate cancer. Many second-generation Androgen receptor signaling antagonists are given either as single agent or with the combination of other drugs. In order to develop a cure for metastasized prostate cancer cells, Androgen deprivation therapy (ADT) is applied by using surgical or chemical methods. In many cases, Prostatectomy or local radiotherapy are used to control metastasized prostate cancer. However, it has been observed that after 1.5 years to 2 years of Prostatectomy or castration, there is reoccurrence of prostate cancer and high incidence of castration resistant prostate cancer is seen in population undergone ADT. It has been observed that Androgen derivation therapy combined with drugs like abiraterone acetate or docetaxel improve overall survival rate in metastatic hormone sensitive prostate cancer (mHSPC) patients. Scientific investigations have revealed that drugs inhibiting poly ADP Ribose polymerase (PARP) are showing promising results in clinical trials in the prostate cancer population with mCRPC and DNA repair abnormalities. Recently, RISUG adv (reversible inhibition of sperm under guidance) has shown significant results against prostate cancer cell lines and MTT assay has validated substantial effects of this drug against PC3 cell lines. Current review paper highlights the advancements in prostate cancer therapeutics and new drug molecules against prostate cancer. It will provide detailed insights on the signaling pathways which need to be targeted to combat metastasized prostate cancer and castration resistant prostate cancer.https://www.frontiersin.org/articles/10.3389/fonc.2023.1193736/fullprostate cancerandrogen deprivation therapycastration resistant prostate cancerRISUG advpoly ADP ribose polymeraseAR signaling |
| spellingShingle | Neha Thakur Sameer Quazi Sameer Quazi Sameer Quazi Sameer Quazi Sameer Quazi Bindu Naik Saurabh Kumar Jha Saurabh Kumar Jha Saurabh Kumar Jha Pallavi Singh RETRACTED: New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics Frontiers in Oncology prostate cancer androgen deprivation therapy castration resistant prostate cancer RISUG adv poly ADP ribose polymerase AR signaling |
| title | RETRACTED: New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics |
| title_full | RETRACTED: New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics |
| title_fullStr | RETRACTED: New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics |
| title_full_unstemmed | RETRACTED: New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics |
| title_short | RETRACTED: New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics |
| title_sort | retracted new insights into molecular signaling pathways and current advancements in prostate cancer diagnostics therapeutics |
| topic | prostate cancer androgen deprivation therapy castration resistant prostate cancer RISUG adv poly ADP ribose polymerase AR signaling |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1193736/full |
| work_keys_str_mv | AT nehathakur retractednewinsightsintomolecularsignalingpathwaysandcurrentadvancementsinprostatecancerdiagnosticstherapeutics AT sameerquazi retractednewinsightsintomolecularsignalingpathwaysandcurrentadvancementsinprostatecancerdiagnosticstherapeutics AT sameerquazi retractednewinsightsintomolecularsignalingpathwaysandcurrentadvancementsinprostatecancerdiagnosticstherapeutics AT sameerquazi retractednewinsightsintomolecularsignalingpathwaysandcurrentadvancementsinprostatecancerdiagnosticstherapeutics AT sameerquazi retractednewinsightsintomolecularsignalingpathwaysandcurrentadvancementsinprostatecancerdiagnosticstherapeutics AT sameerquazi retractednewinsightsintomolecularsignalingpathwaysandcurrentadvancementsinprostatecancerdiagnosticstherapeutics AT bindunaik retractednewinsightsintomolecularsignalingpathwaysandcurrentadvancementsinprostatecancerdiagnosticstherapeutics AT saurabhkumarjha retractednewinsightsintomolecularsignalingpathwaysandcurrentadvancementsinprostatecancerdiagnosticstherapeutics AT saurabhkumarjha retractednewinsightsintomolecularsignalingpathwaysandcurrentadvancementsinprostatecancerdiagnosticstherapeutics AT saurabhkumarjha retractednewinsightsintomolecularsignalingpathwaysandcurrentadvancementsinprostatecancerdiagnosticstherapeutics AT pallavisingh retractednewinsightsintomolecularsignalingpathwaysandcurrentadvancementsinprostatecancerdiagnosticstherapeutics |